Squarepoint Ops LLC Purchases New Stake in SI-BONE, Inc. (NASDAQ:SIBN)

Squarepoint Ops LLC purchased a new position in SI-BONE, Inc. (NASDAQ:SIBN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 32,060 shares of the company's stock, valued at approximately $449,000. Squarepoint Ops LLC owned approximately 0.08% of SI-BONE at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. American Century Companies Inc. grew its position in SI-BONE by 11.0% during the 4th quarter. American Century Companies Inc. now owns 2,378,068 shares of the company's stock worth $33,341,000 after purchasing an additional 236,167 shares during the last quarter. Silvercrest Asset Management Group LLC grew its holdings in SI-BONE by 21.9% during the fourth quarter. Silvercrest Asset Management Group LLC now owns 1,953,806 shares of the company's stock worth $27,392,000 after acquiring an additional 350,970 shares during the period. Nuveen Asset Management LLC raised its position in SI-BONE by 17.8% during the fourth quarter. Nuveen Asset Management LLC now owns 1,263,988 shares of the company's stock valued at $17,721,000 after acquiring an additional 190,830 shares in the last quarter. Geode Capital Management LLC raised its position in SI-BONE by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 933,891 shares of the company's stock valued at $13,097,000 after acquiring an additional 9,847 shares in the last quarter. Finally, Impax Asset Management Group plc boosted its position in SI-BONE by 1.1% in the 4th quarter. Impax Asset Management Group plc now owns 766,761 shares of the company's stock worth $10,750,000 after purchasing an additional 8,240 shares in the last quarter. 98.11% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on SIBN. Needham & Company LLC restated a "buy" rating and issued a $24.00 price target on shares of SI-BONE in a research note on Tuesday, May 6th. Truist Financial boosted their price target on shares of SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 target price on shares of SI-BONE in a report on Tuesday, May 6th.

Insider Transactions at SI-BONE

In other SI-BONE news, CFO Anshul Maheshwari sold 9,585 shares of the firm's stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $19.76, for a total value of $189,399.60. Following the sale, the chief financial officer now directly owns 224,507 shares of the company's stock, valued at approximately $4,436,258.32. This trade represents a 4.09% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Laura Francis sold 38,504 shares of the stock in a transaction on Wednesday, May 7th. The stock was sold at an average price of $17.18, for a total value of $661,498.72. Following the completion of the transaction, the chief executive officer now directly owns 302,958 shares in the company, valued at $5,204,818.44. This trade represents a 11.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 92,565 shares of company stock valued at $1,669,871 in the last ninety days. Corporate insiders own 4.00% of the company's stock.

SI-BONE Stock Performance

Shares of SIBN stock traded down $0.16 during mid-day trading on Friday, hitting $18.90. 485,058 shares of the stock were exchanged, compared to its average volume of 382,072. The stock's fifty day simple moving average is $16.00 and its two-hundred day simple moving average is $15.47. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. SI-BONE, Inc. has a 12-month low of $11.70 and a 12-month high of $20.05. The stock has a market capitalization of $805.42 million, a price-to-earnings ratio of -20.54 and a beta of 0.82.

SI-BONE (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.09. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The firm had revenue of $47.29 million for the quarter, compared to the consensus estimate of $45.13 million. On average, analysts forecast that SI-BONE, Inc. will post -0.78 EPS for the current year.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.